Abcam, a leader in life science research tools, has appointed Tommy Thomas as Vice President of Investor Relations as of June 27, 2022. With over 20 years of experience in the sector, including roles at Avantor and Perkin Elmer, Thomas is expected to enhance the company's investor relations and strengthen ties with institutional investors. Michael Baldock, CFO of Abcam, expressed that Thomas's expertise aligns with the company's growth strategy. Abcam aims to differentiate itself further in the marketplace through customer-centric innovation.
Pionyr Immunotherapeutics and Abcam announced an extended collaboration through a new commercial licensing agreement to advance PY314, a novel anti-TREM2 monoclonal antibody for advanced solid tumors. Currently in Phase 1 trials, PY314 aims to modify the tumor microenvironment by targeting immune-suppressive TREM2-expressing macrophages. Pionyr will utilize Abcam's anti-TREM2 antibody to identify these macrophages in tumor samples. This partnership enhances clinical development and supports the creation of a companion diagnostic for more effective cancer treatment.